Warfarin knowledge in patients with atrial fibrillation: Implications for safety, efficacy, and education strategies

Cardiology

Volumn 116, Issue 1, 2010, Pages 61-69

  Smith, Megan B ^a   Christensen, Nedra ^a   Wang, Shiquan ^a   Strohecker, Jennifer ^b   Day, John D ^b   Weiss, J Peter ^b   Crandall, Brian G ^b   Osborn, Jeffrey S ^b   Anderson, Jeffrey L ^b   Horne, Benjamin D ^b   Muhlestein, Joseph B ^b   Lappe, Donald L ^b   Moss, Heidi ^a   Oliver, Jessica ^a   Viau, Krista ^a   Bunch, T Jared ^a,b  

^a UTAH STATE UNIVERSITY   (United States)

^b INTERMOUNTAIN MEDICAL CENTER   (United States)

Author keywords

Anticoagulants; Atrial fibrillation; Hemorrhage; International normalized ratio; Nutrition; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; CHONDROITIN; FISH OIL; GLUCOSAMINE; HERBACEOUS AGENT; MELATONIN; MULTIVITAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RETINOL; UBIDECARENONE; VITAMIN D; WARFARIN;

AGED; ALCOHOL CONSUMPTION; ANTICOAGULATION; ARTICLE; BLOOD TRANSFUSION; COLLEGE; DIABETES MELLITUS; DIET; DRUG EFFICACY; DRUG SAFETY; FALLING; FEMALE; FOOD INTAKE; HEALTH SURVEY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HIGH SCHOOL; HUMAN; HYPERTENSION; INTERVIEW; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRIORITY JOURNAL; QUESTIONNAIRE; RISK FACTOR; STROKE; TRANSIENT ISCHEMIC ATTACK;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; DRUG INTERACTIONS; FEMALE; FOOD; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HERB-DRUG INTERACTIONS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT EDUCATION AS TOPIC; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 77952532175     PISSN: 00086312     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314936     Document Type: Article

References (32)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE: Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA 2001; 285: 2370-2375.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS: Secular trends in incidence of atrial fibrillation in Olmstead county, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
3. Rockson SG, Albers GW: Comparing the guidelines: anticoagulation therapy to optimize stroke prevention in patients with atrial fibrillation. J Am Coll Cardiol 2004; 43: 929-935.
4. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, Singer DE: Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120: 700-705.
5. Oake N, Fergusson DA, Forster AJ, van Walraven C: Frequency of adverse events in patients with poor anticoagulation: a metaanalysis. CMAJ 2007; 176: 1589-1594.
6. Hallak HO, Wedlund PJ, Modi MW, Patel IH, Lewis GL, Woodruff B, Trowbridge AA: High clearance of (S)-warfarin in a warfarinresistant subject. Br J Clin Pharmacol 1993; 35: 327-330.
7. Hulse ML: Warfarin resistance: diagnosis and therapeutic alternatives. Pharmacotherapy 1996; 16: 1009-1017.
8. The International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA: Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
9. Lane DA, Ponsford J, Shelley A, Sirpal A, Lip GYH: Patient knowledge and perceptions of atrial fibrillation and anticoagulant therapy: effects of an educational interventional programme: the West Birmingham Atrial Fibrillation Project. Int J Cardiol 2006; 110: 354-358.
10. Lip GY, Kamath S, Jafri M, Mohammed A, Bareford D: Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Project. Stroke 2002; 33: 238-242.
11. Davis NJ, Billett HH, Cohen HW, Arnsten JH: Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother 2005; 39: 632-636.
12. Tang EO, Lai C, Lee K, Wong R, Cheng G, Chan T: Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 34-39.
13. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ: Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870.
14. Tsang TS, Petty GW, Barnes ME, O'Fallon WM, Bailey KR, Wiebers DO, Sicks JD, Christianson TJ, Seward JB, Gersh BJ: The prevalence of atrial fibrillation of incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. 2003; 42: 93-100.
15. Hu A, Chow C, Dao D, Errett L, Keith M: Factors influencing patient knowledge of warfarin therapy after mechanical heart valve replacement. J Cardiovasc Nurs 2006; 21: 169-175.
16. van Walraven C, Hart RG, Wells GA, Petersen P, Koudstaal PJ, Gullov AL, Hellemons BS, Koefed BG, Laupacis A: A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. Arch Intern Med 2003; 163: 936-943.
17. Crandall MA, Horne BD, Day JD, Anderson JL, Muhlestein JB, Crandall BG, Weiss JP, Osborne JS, Lappé DL, Bunch TJ: Atrial fibrillation significantly increases total mortality and stroke risk beyond that conveyed by the CHADS2 risk factors. Pacing Clin Electrophysiol 2009; 32: 981-986.
18. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL, American College of Cardiology/American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, European Heart Rhythm Association, Heart Rhythm Society: ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e257-e354.
19. Anderson JL, Horne BD, Stevens SM, Grove AS, Barton S, Nicholas ZP, Kahn SF, May HT, Samuelson KM, Muhlestein JB, Carlquist JF, Couma-Gen Investigators: Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007; 116: 2563-2570.
20. Taylor FC, Ramsay ME, Tan G, Gabbay J, Cohen H: Evaluation of patients' knowledge about anticoagulant treatment. Qual Health Care 1994; 3: 79-85.
21. Kurnik D, Loebstein R, Rabinovitz H, Austerweil N, Halkin H, Almog S: Overthe- counter vitamin K1-containing multivitamin supplements disrupt warfarin anticoagulation in vitamin K1-depleted patients. A prospective, controlled trial. Thromb Haemost 2004; 92: 1018-1024.
22. Schurgers LJ, Shearer MJ, Hamulyak K, Stocklin E, Vermeer C: Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood 2004; 104: 2682-2689.
23. Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F: Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol 2004; 124: 348-354.
24. Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, Blumberg JB: Dietary vitamin K variability affects International Normalized Ratio (INR) coagulation indices. Int J Vitam Nutr Res 2006; 76: 65-74.
25. Juurlink DN: Drug interactions with warfarin: what clinicians need to know. CMAJ 2007; 177: 369-371.
26. Barnes PM, Bloom B, Nahin RL: Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2009; 12: 1-23.
27. Heck AM, DeWitt BA, Lukes AL: Potential interactions between alternative therapies and warfarin. Am J Health Syst Pharm 2000; 57: 1221-1227.
28. Parker CS, Chen Z, Price M, Gross R, Metlay JP, Christie JD, Brensinger CM, Newcomb CW, Samaha FF, Kimmel SE: Adherence to warfarin assessed by electronic pill caps, clinician assessment, and patient reports: results from the IN-RANGE study. J Gen Intern Med 2007; 22: 1254-1259.
29. Connolly SJ, Ezekowitz MD, Yusuf S, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
30. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P: Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomized non-inferiority trial. Lancet 2009; 374: 534-542.
31. Wofford JL, Wells MD, Singh S: Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res 2008; 8: 40.
32. Newall F, Monagle P, Johnston L: Patient understanding of warfarin therapy: a review of education strategies. Hematology 2005; 10: 437-442.